New classification system-based visual outcome in Eales' disease.
OBJECTIVE
A retrospective tertiary care center-based study was undertaken to evaluate the visual outcome in Eales' disease, based on a new classification system, for the first time.


METHODS
One hundred and fifty-nine consecutive cases of Eales' disease were included. All the eyes were staged according to the new classification: Stage 1: periphlebitis of small (1a) and large (1b) caliber vessels with superficial retinal hemorrhages; Stage 2a: capillary non-perfusion, 2b: neovascularization elsewhere/of the disc; Stage 3a: fibrovascular proliferation, 3b: vitreous hemorrhage; Stage 4a: traction/combined rhegmatogenous retinal detachment and 4b: rubeosis iridis, neovascular glaucoma, complicated cataract and optic atrophy. Visual acuity was graded as: Grade I 20/20 or better; Grade II 20/30 to 20/40; Grade III 20/60 to 20/120 and Grade IV 20/200 or worse. All the cases were managed by medical therapy, photocoagulation and/or vitreoretinal surgery. Visual acuity was converted into decimal scale, denoting 20/20=1 and 20/800=0.01. Paired t-test / Wilcoxon signed-rank tests were used for statistical analysis.


RESULTS
Vitreous hemorrhage was the commonest presenting feature (49.32%). Cases with Stages 1 to 3 and 4a and 4b achieved final visual acuity ranging from 20/15 to 20/40; 20/80 to 20/400 and 20/200 to 20/400, respectively. Statistically significant improvement in visual acuities was observed in all the stages of the disease except Stages 1a and 4b.


CONCLUSIONS
Significant improvement in visual acuities was observed in the majority of stages of Eales' disease following treatment. This study adds further to the little available evidences of treatment effects in literature and may have effect on patient care and health policy in Eales' disease.
Saxena
Sandeep
S
Department of Ophthalmology, King George's Medical University, Lucknow, India. sandeepsaxena2020@yahoo.com
Kumar
Dipak
D
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017075:Laser Coagulation; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D010689:Phlebitis / Q000145:classification* / Q000150:complications / Q000628:therapy; D011379:Prognosis; D015861:Retinal Neovascularization / Q000145:classification* / Q000150:complications / Q000628:therapy; D012169:Retinal Vein; D012189:Retrospective Studies; D012720:Severity of Illness Index; D014792:Visual Acuity; D014821:Vitrectomy; D014823:Vitreous Hemorrhage / Q000145:classification / Q000209:etiology* / Q000628:therapy
D007166:Immunosuppressive Agents; D008727:Methotrexate